10-K: Lucid Diagnostics Details Share Structure, Preferred Stock Offerings in 10-K Filing

Lucid Diagnostics' 10-K filing outlines its share structure, recent preferred stock offerings, and various agreements with PAVmed, its parent company.

Summary

• Lucid Diagnostics had 44,667,304 shares of common stock outstanding as of December 31, 2023, along with preferred stock convertible into common stock.
• The company has a committed equity facility with Cantor Fitzgerald for up to $50 million and an at-the-market offering for up to $6.5 million of common stock.
• Lucid issued 13,625 shares of Series A Preferred Stock in March 2023, raising $13.625 million, and 5,000 shares of Series A-1 Preferred Stock in October 2023, raising $5 million.
• In March 2024, Lucid issued 44,285 shares of Series B Preferred Stock, with 31,790 shares issued in exchange for all outstanding Series A and A-1 Preferred Stock, raising $18.16 million in total.
• The Series B Preferred Stock has a conversion price of $1.2444 and is a voting security.
• Lucid has a management services agreement with PAVmed, which may be settled in cash or shares of common stock.
• The company is authorized to issue 200,000,000 shares of common stock and 20,000,000 shares of preferred stock.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's share structure and financing activities. While the company has successfully raised capital, there are also risks associated with its dependence on PAVmed and the potential dilution of common stock.

Positives

• The company successfully raised capital through multiple preferred stock offerings.
• The conversion of Series A and A-1 preferred stock into Series B simplifies the capital structure.
• The Series B Preferred Stock is a voting security, which may be attractive to investors.
• Lucid has access to a committed equity facility and an at-the-market offering to raise additional capital.

Negatives

• The issuance of preferred stock could dilute the voting power of common stockholders.
• The company is dependent on PAVmed for management services and may be subject to conflicts of interest.
• PAVmed has the ability to control the election of all members of the board of directors.
• The company has not paid any cash dividends on its common stock to date and does not anticipate doing so in the foreseeable future.

Risks

• The issuance of preferred stock could adversely affect the voting power of common stockholders.
• The company is subject to anti-takeover provisions that could make it difficult to acquire.
• The company is dependent on PAVmed for management services and may be subject to conflicts of interest.
• The company's board of directors has the authority to issue preferred stock without stockholder approval.
• The company is subject to Section 203 of the DGCL, which could discourage mergers or takeovers.
• The company's bylaws include advance notice procedures for stockholder proposals and director nominations, which may limit stockholder actions.

Future Outlook

The company intends to retain all earnings for use in business operations and does not anticipate declaring any dividends in the foreseeable future.

Management Comments

• The board of directors has the authority to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof.
• The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition and will be within the discretion of our Board of Directors.

Industry Context

The document highlights the company's efforts to secure funding and manage its capital structure, which is a common challenge for early-stage medical diagnostics companies. The reliance on a parent company for management services is also a common practice in the industry.

Comparison to Industry Standards

• The use of convertible preferred stock is a common method for early-stage companies to raise capital, similar to companies like Exact Sciences and Guardant Health.
• The reliance on a parent company for management services is similar to other spin-off or subsidiary companies in the medical device and diagnostics space.
• The company's focus on securing Medicare payment determination is a standard practice for companies in the diagnostics industry, similar to companies like Myriad Genetics and Genomic Health.
• The company's use of at-the-market offerings and committed equity facilities is a common practice for publicly traded companies to raise capital, similar to companies like Invitae and Natera.

Related Party Transactions

• Lucid has a management services agreement with PAVmed, which may be settled in cash or shares of common stock.
• Lucid has a payroll and benefits expense reimbursement agreement with PAVmed, which may be settled in cash or shares of common stock.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of preferred stock and potential future equity offerings.
• Shareholders may be impacted by the company's dependence on PAVmed and potential conflicts of interest.
• Employees may be impacted by changes in management or compensation policies.
• Customers may be impacted by the company's ability to commercialize its products and secure reimbursement from third-party payors.

Next Steps

• The company will continue to utilize its committed equity facility and at-the-market offering to raise additional capital.
• The company will continue to pursue commercialization of its products and seek reimbursement from third-party payors.
• The company will continue to develop its products and conduct clinical trials.

Key Dates

Keywords

preferred stock, common stock, convertible securities, capital raise, management services agreement, PAVmed, equity facility, at-the-market offering, corporate governance, share structure